Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Mark Awad, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Mark Awad and Leena Gandhi.
Connection Strength

0.466
  1. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):124-129.
    View in: PubMed
    Score: 0.199
  2. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 2017 02; 104:126-130.
    View in: PubMed
    Score: 0.178
  3. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103.
    View in: PubMed
    Score: 0.046
  4. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov; 17(11):1497-1508.
    View in: PubMed
    Score: 0.044
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.